Cutaneous melanoma · line 2 · Encorafenib + binimetinib (BRAF V600E/K melanoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ENCORAFENIB-BINIMETINIB-MELANOMA |
| ID | IND-MELANOMA-2L-POST-IO-BRAFI-MEKI |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MELANOMA |
| Sources | SRC-COLUMBUS-DUMMETT-2018 SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L for BRAF V600+ metastatic melanoma after 1L IO. Sequencing rationale per DREAMseq: IO-first → BRAFi+MEKi-second yields superior OS vs the reverse sequence. Tolerability advantage of ENCO+BINI over DABRA+TRAME and vemurafenib mono drives our default ranking, but DABRA+TRAME (REG-DABRAFENIB-TRAMETINIB-NSCLC) is fully interchangeable per NCCN cat 1.
Used By
Algorithms
ALGO-MELANOMA-METASTATIC-2L- ALGO-MELANOMA-METASTATIC-2L